Jithin Yohannan1, Jiangxia Wang1, Jamie Brown1, Balwantray C Chauhan2, Michael V Boland1, David S Friedman1, Pradeep Y Ramulu3. 1. Glaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland. 2. Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, Nova Scotia, Canada. 3. Glaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland. Electronic address: pramulu@jhmi.edu.
Abstract
PURPOSE: Assess the impact of false-positives (FP), false-negatives (FN), fixation losses (FL), and test duration (TD) on visual field (VF) reliability at different stages of glaucoma severity. DESIGN: Retrospective. PARTICIPANTS: A total of 10 262 VFs from 1538 eyes of 909 subjects with suspect or manifest glaucoma and ≥5 VF examinations. METHODS: Predicted mean deviation (MD) was calculated with multilevel modeling of longitudinal data. Differences between predicted and observed MD (ΔMD) were calculated as a reliability measure. The impact of FP, FN, FL, and TD on ΔMD was assessed using multilevel modeling. MAIN OUTCOME MEASURES: ΔMD associated with a 10% increment in FP, FN, and FL, or a 1-minute increase in TD. RESULTS: FL had little impact on ΔMD (<0.2 decibels [dB] per 10% abnormal catch trials), and no level of FL produced ≥1 dB of ΔMD at any disease stage. FP yielded greater than expected MD, with a 10% increment in abnormal catch trials associated with a ΔMD = 0.42, 0.73, and 0.66 dB in mild (MD >-6 dB), moderate (-6 ≤MD <-12 dB), and severe (-12 ≤MD ≤-20 dB) disease, respectively, up to 20% abnormal catch trials, and a ΔMD = 1.57, 2.06, and 3.53 dB beyond 20% abnormal catch trials. FNs generally produced observed MDs below expected MDs. FN were minimally impactful up to 20% abnormal catch trials (ΔMD per 10% increment >-0.14 dB at all levels of severity). Beyond 20% abnormal catch trials, each 10% increment in abnormal catch trials was associated with a ΔMD = -1.27, -0.53, and -0.51 dB in mild, moderate, and severe disease, respectively. |ΔMD| ≥1 dB occurred with 22% FP and 26% FN in early, 14% FP and 34% FN in moderate, and 16% FP and 51% FN in severe disease. A 1-minute increment in TD produced ΔMDs between -0.35 and -0.40 dB. CONCLUSIONS: FL have little impact on reliability in patients with established glaucoma. FP, and to a lesser extent FNs and TD, significantly affect reliability. The impact of FP and FN varies with disease severity and over the range of abnormal catch trials. On the basis of our findings, we present evidence-based, severity-specific standards for classifying VF reliability for clinical or research applications.
PURPOSE: Assess the impact of false-positives (FP), false-negatives (FN), fixation losses (FL), and test duration (TD) on visual field (VF) reliability at different stages of glaucoma severity. DESIGN: Retrospective. PARTICIPANTS: A total of 10 262 VFs from 1538 eyes of 909 subjects with suspect or manifest glaucoma and ≥5 VF examinations. METHODS: Predicted mean deviation (MD) was calculated with multilevel modeling of longitudinal data. Differences between predicted and observed MD (ΔMD) were calculated as a reliability measure. The impact of FP, FN, FL, and TD on ΔMD was assessed using multilevel modeling. MAIN OUTCOME MEASURES: ΔMD associated with a 10% increment in FP, FN, and FL, or a 1-minute increase in TD. RESULTS:FL had little impact on ΔMD (<0.2 decibels [dB] per 10% abnormal catch trials), and no level of FL produced ≥1 dB of ΔMD at any disease stage. FP yielded greater than expected MD, with a 10% increment in abnormal catch trials associated with a ΔMD = 0.42, 0.73, and 0.66 dB in mild (MD >-6 dB), moderate (-6 ≤MD <-12 dB), and severe (-12 ≤MD ≤-20 dB) disease, respectively, up to 20% abnormal catch trials, and a ΔMD = 1.57, 2.06, and 3.53 dB beyond 20% abnormal catch trials. FNs generally produced observed MDs below expected MDs. FN were minimally impactful up to 20% abnormal catch trials (ΔMD per 10% increment >-0.14 dB at all levels of severity). Beyond 20% abnormal catch trials, each 10% increment in abnormal catch trials was associated with a ΔMD = -1.27, -0.53, and -0.51 dB in mild, moderate, and severe disease, respectively. |ΔMD| ≥1 dB occurred with 22% FP and 26% FN in early, 14% FP and 34% FN in moderate, and 16% FP and 51% FN in severe disease. A 1-minute increment in TD produced ΔMDs between -0.35 and -0.40 dB. CONCLUSIONS:FL have little impact on reliability in patients with established glaucoma. FP, and to a lesser extent FNs and TD, significantly affect reliability. The impact of FP and FN varies with disease severity and over the range of abnormal catch trials. On the basis of our findings, we present evidence-based, severity-specific standards for classifying VF reliability for clinical or research applications.
Authors: Karun S Arora; Michael V Boland; David S Friedman; Joan L Jefferys; Sheila K West; Pradeep Y Ramulu Journal: Ophthalmology Date: 2013-08-30 Impact factor: 12.079
Authors: Anders Heijl; Boel Bengtsson; Balwantray C Chauhan; Marc F Lieberman; Ian Cunliffe; Leslie Hyman; M Cristina Leske Journal: Ophthalmology Date: 2008-04-18 Impact factor: 12.079
Authors: Frank C Curriero; Jessie Pinchoff; Suzanne W van Landingham; Luigi Ferrucci; David S Friedman; Pradeep Y Ramulu Journal: JAMA Ophthalmol Date: 2013-11 Impact factor: 7.389
Authors: Pradeep Y Ramulu; Chad Hochberg; Eugenio A Maul; Emilie S Chan; Luigi Ferrucci; David S Friedman Journal: Optom Vis Sci Date: 2014-02 Impact factor: 1.973
Authors: Moon Jeong Lee; Jiangxia Wang; David S Friedman; Michael V Boland; Carlos G De Moraes; Pradeep Y Ramulu Journal: Ophthalmology Date: 2018-10-10 Impact factor: 12.079
Authors: Jithin Yohannan; Michael Cheng; Joseph Da; Sagar Chapagain; Ayodeji Sotimehin; Luke W Bonham; Aleksandra Mihailovic; Michael Boland; Pradeep Ramulu Journal: Ophthalmology Date: 2019-08-29 Impact factor: 12.079
Authors: Jian-Yu E; Jennifer A Schrack; Aleksandra Mihailovic; Amal A Wanigatunga; Sheila K West; David S Friedman; Laura N Gitlin; Tianjing Li; Pradeep Y Ramulu Journal: Ophthalmology Date: 2020-06-29 Impact factor: 12.079
Authors: Dominic J Grisafe; Rohit Varma; Bruce S Burkemper; Benjamin Y Xu; Mina Torres; Alicia Fairbrother-Crisp; Cecilia M Patino; Roberta McKean-Cowdin Journal: Am J Ophthalmol Date: 2021-02-08 Impact factor: 5.488
Authors: Andrew Steven Camp; Christopher P Long; Vincent Michael Patella; James A Proudfoot; Robert N Weinreb Journal: Am J Ophthalmol Date: 2021-07-17 Impact factor: 5.488